CDC updates clinical guidance on treating COVID-19 recurrence after antiviral pill
The Centers for Disease Control and Prevention today released for clinicians treating COVID-19 in patients who received the Pfizer COVID-19 antiviral pill Paxlovid.
鈥淭here is currently no evidence that additional treatment is needed with Paxlovid or other anti-SARS-CoV-2 therapies in cases where COVID-19 rebound is suspected,鈥 CDC said, noting that a brief return of symptoms may be part of the natural history of SARS-CoV-2 infection in some individuals, 鈥渋ndependent of treatment with Paxlovid and regardless of vaccination status.鈥
CDC continues to recommend Paxlovid to treat mild to moderate COVID-19 in patients at high risk for progressing to severe disease and when COVID-19 rebounds to manage transmission risk.
Related News Articles
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.鈥檚 nomination for secretary of the Department of Health and Human Services. A鈥
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the鈥
Headline
CDC recommends two doses of COVID-19 vaccine for older individuals, lowers pneumococcal vaccine age聽
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to鈥
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their鈥
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers鈥
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a鈥